)
Wimal Kapadia, MSc
Vice President of Search, Evaluation & Intelligence
Novo Nordisk
Wimal holds a BSc in Biotechnology and an MSc in Biochemical Engineering from the University College of London (UCL). Wimal joined Novo Nordisk from Bernstein Autonomous where he was partner leading the EU Biopharmaceutical equity research team analyzing Novo Nordisk as well as large cap Biopharma peers. Wimal joined Bernstein in 2014, assuming increasing responsibility for the sector, establishing himself as a long-term stock analyst and thought leader on several topics within financial markets including diabetes and obesity. Prior to Bernstein, Wimal worked for several years at JP Morgan primarily within the EU Biopharmaceutical equity research team, spending time on the derivatives trading floor and started his career at JP Morgan within the investment banking division. At Novo Nordisk, Wimal is Vice President of Search, Evaluation & Intelligence within Corporate Development.
Sessions
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}